Opinion: Pricing info with new drug approvals: Time for transparency
For years Congress has raised concerns with the way some drugmakers pay to delay generic versions of their branded blockbusters, as well as other patent …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
